CIK 0001517022 · Large accelerated filer
Akebia Therapeutics, Inc.
Sign in to watch- Ticker
- AKBA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 208756903
- Phone
- 617-871-2098
- Business address
- 180 THIRD AVENUE, FLOOR 2, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-06 | ADAMS ADRIAN Director | Grant or award · Stock Option (Right to buy) | +45,000 | 45,000 | ||
| 2024-05-13 | Hadas Nicole R. SVP, Chief Legal Officer | Sale 10b5-1 | −12,016 | $1.26 | $15K | 651,243 |
| 2024-05-13 | Dahan Michel SVP, Chief Operating Officer | Sale 10b5-1 | −34,840 | $1.26 | $44K | 672,092 |
| 2024-02-29 | Dahan Michel SVP, Chief Operating Officer | Sale | −8,661 | $1.58 | $14K | 706,932 |
| 2024-02-29 | Hadas Nicole R. SVP, Chief Legal Officer | Sale | −5,974 | $1.58 | $9K | 663,259 |
| 2024-02-29 | Butler John P. CEO and President | Sale | −46,570 | $1.58 | $74K | 2,044,580 |
| 2024-02-29 | Burke Steven Keith SVP, Chief Medical Officer | Sale | −7,169 | $1.58 | $11K | 695,840 |
| 2024-02-27 | Hadas Nicole R. SVP, Chief Legal Officer | Sale 10b5-1 | −7,411 | $1.52 | $11K | 669,233 |
| 2024-02-27 | Dahan Michel SVP, Chief Operating Officer | Sale | −10,744 | $1.52 | $16K | 715,593 |
| 2024-02-27 | Burke Steven Keith SVP, Chief Medical Officer | Sale 10b5-1 | −8,367 | $1.52 | $13K | 703,009 |
| 2024-02-27 | Butler John P. CEO and President | Sale | −37,733 | $1.52 | $57K | 2,091,150 |
| 2024-02-01 | Butler John P. CEO and President | Sale | −46,489 | $1.68 | $78K | 2,128,883 |
| 2024-02-01 | Burke Steven Keith SVP, Chief Medical Officer | Sale | −24,311 | $1.68 | $41K | 711,376 |
| 2024-01-31 | Grund Nicholas Chief Commercial Officer | Grant or award | +303,300 | 303,300 | ||
| 2024-01-31 | Grund Nicholas Chief Commercial Officer | Grant or award · Stock Option (Right to buy) | +454,950 | 454,950 | ||
| 2024-01-31 | Malabre Richard C Chief Accounting Officer | Grant or award | +223,950 | 223,950 | ||
| 2024-01-31 | Malabre Richard C Chief Accounting Officer | Grant or award · Stock Option (Right to buy) | +336,000 | 336,000 | ||
| 2024-01-31 | Dahan Michel SVP, Chief Operating Officer | Grant or award | +149,300 | 726,337 | ||
| 2024-01-31 | Dahan Michel SVP, Chief Operating Officer | Grant or award · Stock Option (Right to buy) | +224,000 | 224,000 | ||
| 2024-01-31 | Snow Ellen SVP, CFO and Treasurer | Grant or award | +149,300 | 519,300 |
Page 6 of 21 · 405 trades